slide1 n.
Skip this Video
Loading SlideShow in 5 Seconds..
Reports and Intelligence: Non-Small Cell Lung Cancer Market PowerPoint Presentation
Download Presentation
Reports and Intelligence: Non-Small Cell Lung Cancer Market

Loading in 2 Seconds...

play fullscreen
1 / 6

Reports and Intelligence: Non-Small Cell Lung Cancer Market - PowerPoint PPT Presentation

  • Uploaded on

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about 'Reports and Intelligence: Non-Small Cell Lung Cancer Market ' - RyanAddison111

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

Non-Small Cell Lung Cancer Market to 2020

New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market

Published on: July 2014

No. of Pages: 143

Reports and Intelligence


GBI Research, a leading business intelligence provider, has released its latest research report, “Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market”. The value of the Non-Small Cell Lung Cancer (NSCLC) market is expected to increase significantly over the forecast period across the leading eight developed nations, from $5.1 billion in 2013 to $7.9 billion in 2020. This equates to a Compound Annual Growth Rate (CAGR) of 6.6%. Growth will be driven by novel therapies entering the squamous cell carcinoma market segment, which is currently lacking effective treatment, unlike the non-squamous market segment.

The report focuses on the increasing differentiation between the three main NSCLC subtypes: squamous cell, adenocarcinoma, and large cell carcinoma. Common genetic and molecular aberrations within these histologies are being extensively researched and targeted by novel therapeutics and so the treatment algorithm between histological subtypes is forecast to become more differentiated over the forecast period. Most notably, patients with squamous cell carcinoma are set to benefit from crucial first- and second-line therapies in the form of Yervoy (ipilimumab) and nivolumab, having relied on generic chemotherapy for the past decade. 

table of content
Table Of Content


Marketed Products

NSCLC Pipeline

Market Forecast

Strategic Consolidations


Get full access to TOC at:

  • A disease introduction, which defines the disease and looks at symptoms, diagnosis and treatment
  • Analysis of the NSCLC marketed landscape, including a comparison of the efficacy and safety of the most prominent brands, as well as the unmet needs of NSCLC treatment
  • Detailed analysis of the NSCLC pipeline, covering among other parameters, drug distribution by Phase, molecule type and mechanism of action. The NSCLC clinical trial landscape is analyzed with particular emphasis on failure rates across different trial Phases, as well as the trends in clinical trial size, duration and primary endpoint. This section also includes profiles and single product forecasts for the most promising pipeline drugs.
  • An epidemiological forecast of the major NSCLC markets, in which projected values include total and treated populations
  • An overview of the drivers of and barriers to the NSCLC market
reasons to buy
Reasons To Buy
  • Understand the NSCLC pipeline and the clinical needs that it is addressing, particularly the ways in which histology affects treatment options and where in the treatment algorithm new products will be positioned, as well as where unmet needs remain
  • Develop their knowledge of key products that may enter the market before 2020. Detailed profiles of these products are provided, with a focus on their clinical trial performance, as well as how they can be incorporated into the NSCLC treatment plan and what competition they face.
  • Assess the risk associated with NSCLC product development profiled by molecule type and mechanism of action and compared with both industry and therapy-area averages. In addition, data analyses offer a more detailed understanding of the trends in both trial size and duration for specific mechanisms of action or molecule types. The primary endpoint analysis infers trends in trial design within the therapy area, as well as the endpoints that are the best indicators of success.

Get access to detailed information at:

Request for Discount at: